Smartwatches flood users with heart-rate trends, sleep scores and irregular-rhythm alerts. Physicians see the potential. Yet few act on it.
A fresh survey of more than 2,200 doctors across six countries reveals the gap. Seventy-seven percent of U.S. physicians recognize a clinical advantage in wearable data. Only 6 percent have folded it into daily practice. The numbers come from the American Medical Association, published just days ago. They match findings reported two years earlier but show little progress.
“We have all this data that’s available, but it’s actually not actionable because we don’t have a way to get it into clinical workflow,” AMA CEO Dr. John Whyte told Healthcare Dive. The quote still stings. Systems remain built for episodic visits, not continuous streams.
And the streams keep growing. Global wearable shipments near 614 million units this year. The clinical-grade segment expands at 25 percent annually as once-novel sensors earn FDA clearance. Apple’s sleep-apnea detection and Withings’ AFib feature now feed directly into Epic and Cerner records at select accountable-care organizations. Cardiologists lead adoption. They cite relevance to arrhythmias, heart failure and post-MI monitoring.
But relevance alone does not create workflow. Data arrives in incompatible formats. EHR integration lags. Doctors must decide whether to trust measurements taken outside controlled settings. A 2026 pilot in the European Heart Journal Digital Health found smartwatches delivered reliable heart-rate and ECG readings even in advanced heart-failure patients with left-ventricular assist devices. Impressive. Still, one study does not quiet broader doubts.
Stanford Medicine researchers demonstrated years ago that smartwatch metrics can predict shifts in blood tests. Rising skin temperature paired with reduced movement signaled higher immune-cell counts and inflammation. Continuous tracking sometimes spotted changes earlier than lab draws. Useful signals exist. Clinicians need confidence they apply to the patient in front of them.
Regulatory signals have shifted. On January 6, 2026, the FDA issued guidance that non-invasive wearables offering wellness information generally escape formal oversight. Devices may direct users to see a provider when readings stray from wellness ranges without triggering medical-device status. FDA Commissioner Makary said at the time, “Let’s let doctors choose from a competitive marketplace which ones they recommend for their patients.” The move cheered manufacturers. It also left physicians sorting reliable tools from clever gadgets.
Earlier, the agency sent a warning letter to WHOOP over its blood-pressure insights feature. That episode drew a line: certain claims cross into regulated territory. The boundary remains regulatory, not technological. A smartwatch becomes medical when it makes medical claims.
Payment questions compound the hesitation. U.S. CPT codes for remote physiologic monitoring demand FDA-cleared devices deployed under a clinician-directed plan of care. Consumer wearables, even those with cleared features, often fall outside reimbursement. Doctors in Germany, where pathways appear clearer, incorporate wearable data more readily. Time spent reviewing wrist-derived trends must be compensated or it competes with other tasks.
Specialists differ sharply. Cardiologists and endocrinologists show higher workflow integration than generalists. The AMA survey highlighted this pattern. When data maps directly to a specialty’s decisions, physicians invest effort to make it usable. Otherwise it sits in patient portals, unread.
Oura and Whoop now embed video-chat links to physicians inside their apps. Early pilots aim to close the loop between data and advice. Evidence remains thin. FDA has cleared only select features. Clinicians ask whether the stream justifies added liability or workload.
Companies push forward. Apple Watch Ultra 3 bundles AI-driven vitals summaries and medication-interaction alerts. Samsung and Garmin tout ECG functions with longer battery life. These devices target both consumers and clinical pilots. Yet a Sahha AI analysis from June notes the fastest growth lies in medical-grade wearables rather than consumer models. The distinction matters. Clearance changes everything about trust and billing.
Insurance carriers watch closely. Some pilot programs reimburse prescribed wearables for high-risk cardiac patients. Others wait for larger outcome trials. The lag frustrates engineers who spent years refining sensors. It also leaves patients carrying six weeks of atrial-fibrillation alerts into appointments only to watch physicians glance and set the report aside.
Interoperability projects gain traction. Apple Health records now appear in some EHRs as supplementary information. Withings ScanWatch 2 data flows into hospital systems at dozens of organizations. These connections represent incremental wins. They do not yet form a standard.
Privacy adds another layer. Patients own their data in theory. In practice, sharing requires consent, secure transfer and clear rules on secondary use. An opinion paper published this year in PMC warned that hardware and software variability complicates integration into clinical or population studies. Accuracy, reliability and standardization remain open questions.
But. Progress appears in targeted areas. Cancer centers test wearables for remote monitoring during treatment. One presentation at the 2026 AACR meeting showed benefits for individualized decisions. Remote-patient-monitoring platforms pull real-time vitals from multiple devices into unified dashboards. AI flags anomalies for physician review. These tools reduce alert fatigue when tuned properly.
So the hardware outpaces the system around it. Sensors improve yearly. Clinical workflows adapt slowly. Reimbursement policies trail both. Until doctors can bill for time spent interpreting wearable trends, until data lands cleanly inside EHRs, until validation studies accumulate, the promise stays partial.
Recent guidance from the FDA may accelerate physician comfort. Limited oversight for wellness features could spur more recommendations. Yet the same document cautions against over-reliance on unverified glucose claims or blood-pressure estimates. Balance matters.
Cardiology has moved farthest. A 2026 pilot study confirmed smartwatches track heart-failure patients effectively. Garmin’s 14-day battery life suits those who dislike daily charging. Samsung’s AI features appeal to rhythm specialists. These examples point a direction. Broader specialties lag.
Patients expect action. They buy devices, grant permissions, generate reports. When physicians dismiss the information, trust erodes on both sides. The fix requires coordinated effort among regulators, payers, EHR vendors and device makers. No single company can solve workflow or reimbursement alone.
New articles this week reinforce the pattern. The AMA’s international survey, covered by EMF Radar, shows interest without integration. Top Doctor Magazine reviewed physician recommendations and noted growing prescription of ECG-capable watches for arrhythmia patients. Each piece adds detail but reaches the same conclusion: data collection has matured. Clinical action has not.
Expect more capable watches later this year. Apple, Samsung and Google prepare updates. Features will impress on stage. Real impact depends on what happens after the patient leaves the store and the data reaches a doctor’s inbox. That inbox still needs better tools, clearer payment and stronger evidence.
The wrist has become a sophisticated sensor platform. Medicine has yet to treat it as standard equipment. Closing that gap will demand changes deeper than new hardware. It will require rewriting how physicians receive, trust and get paid for continuous patient data. Until then, smartwatches remain excellent collectors and reluctant clinical partners.
WebProNews is an iEntry Publication